Federal Register of Legislation - Australian Government

Primary content

SR 1980 No. 213 Regulations as made
These Regulations amend the National Health (Pharmaceutical Benefits) Regulations.
Administered by: Health
General Comments: This instrument was backcaptured in accordance with Section 36 of the Legislative Instruments Act 2003
Registered 01 Jan 2005
Tabling HistoryDate
Tabled HR19-Aug-1980
Tabled Senate19-Aug-1980
Gazetted 29 Jul 1980
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

Statutory Rules

1980 No. 213

REGULATIONS UNDER THE NATIONAL HEALTH ACT 19531

WHEREAS it is provided by sub-section 101 (4) of the National Health Act 1953 that a drug or medicinal preparation that was not a pharmaceutical benefit under that Act immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

            AND WHEREAS that Committee has recommended to the Minister that the following drugs and medicinal preparations be prescribed as pharmaceutical benefits under section 85 of the National Health Act 1953, namely the drugs and medicinal preparations specified in Schedule 3 to the National Health (Pharmaceutical Benefits) Regulations, as amended by the following Regulations, that had not previously been prescribed as pharmaceutical benefits:

            NOW THEREFORE I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953.

          Dated this twenty-second day of July 1980.

                                                                                                                           ZELMAN COWEN

                                                                                                                           Governor-General

          By His Excellency’s Command,

 

MICHAEL MACKELLAR

Minister of State for Health

_______________

AMENDMENTS OF THE NATIONAL HEALTH
(PHARMACEUTICAL BENEFITS) REGULATIONS2

1              Commencement

                These Regulations shall come into operation on 1 August 1980.

2              Schedule 1

                Schedule 1 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 1.

3              Schedule 2

                Schedule 2 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 2.

4              Schedule 3

                Schedule 3 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 3.

5              Schedule 5

                Schedule 5 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 4.

_________

                                           SCHEDULE 1                            Regulation 2

AMENDMENTS OF SCHEDULE 1 TO THE NATIONAL HEALTH (PHARMACEUTICAL (PHARMACEUTICAL BENEFITS) REGULATIONS

       1.       Omit Item 5.

       2.       Omit Item 288.

       3.       After Item 605 insert the following item:

                     “605A    Primidone”.

       4.       After Item 703 insert the following item:

                     “703A    Sulphadimidine”.

__________

                                           SCHEDULE 2                            Regulation 3

AMENDMENTS OF SCHEDULE 2 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

       1.       After Item 4 insert the following item:

“4A

Adrenaline Acid Tartrate, B.P.

Pilocarpine Hydrochloride, B.P., with Adrenaline Acid Tartrate, B.P.”.

       2.       After Item 104 insert the following item:

“104A

Frusemide

—”.

       3.       After Item 123 insert the following item:

“123A

Insulin Injection, Neutral
Specially Purified

Insulin Isophane Injection, Specially Purified, and Insulin Injection, Neutral Specially Purified”.

       4.       After Item 123A insert the following item:

“123B

Insulin Isophane Injection,
Specially Purified

Insulin Injection, Neutral Specially Purified, and Insulin Isophane Injection, Specially Purified”.

       5.       Omit Item 134, substitute the following item:

“134

Lynoestrenol

Ethinyloestradiol with Lynoestrenol”.

       6.       Omit Item 142, substitute the following item:

“142

Mestranol

Ethynodiol Diacetate with Mestranol Norethisterone with Mestranol Norethynodrel with Mestranol”.

       7.       Omit Item 183.

       8.       Omit Item 201.

       9.       After Item 227 insert the following item:

“227A

Vidarabine

—”.

__________

                                           SCHEDULE 3                            Regulation 4

AMENDMENTS OF SCHEDULE 3 TO THE NATIONAL HEALTH (PHARMACEUTICAL (PHARMACEUTICAL BENEFITS) REGULATIONS

       1.       Omit Item 122.

       2.       Omit Item 221, substitute the following item:

“221.

Oxycodone Hydrochloride”.

 

       3.       After Item 336 insert the following item:

“336A

Vidarabine”.

 

__________

                                           SCHEDULE 4                            Regulation 5

AMENDMENTS OF SCHEDULE 5 TO THE NATIONAL HEALTH (PHARMACEUTICAL (PHARMACEUTICAL BENEFITS) REGULATIONS

       1.       Omit Item 53, substitute the following item:

“53

‘DE-LACT INFANT’

Acute gastro-enteritis, complicated by lactose intolerance, in infants under the age of 6 months’.

       2.       Omit Item 65, substitute the following item:

“65

Dipyridamole

With the written authority of the Permanent Head—

     Supplementing anticoagulents in—

          Biopsy proven glomerulonephritis
Microangiopathic renal disease
Renal allograft
Patients with cardiac prosthesis”.

       3.       Omit from Item 84 “, 1.5 mg”.

       4.       Omit Items 85 and 86.

       5.       Omit Item 92, substitute the following item:

“92

  (1)  Insulin Injection, Biphasic Specially Purified—Monocomponent

Insulin resistance, insulin allergy, disabling local reactions or atrophy Juvenile diabetes

 

  (2)  Insulin Injection, Neutral Specially Purified

Patients already stablilised on this type of insulin”.

 

  (3)  Insulin Injection, Neutral Specially Purified—Monocomponent

 

 

  (4)  Insulin Isophane Injection, Specially Purified, and Insulin Injection, Neutral Specially Purified

 

 

  (5)  Insulin Isophane Injection, Specially Purified—Porcine

 

 

  (6)  Insulin Zinc Suspension Specially Purified Injection—Monocomponent

 

 

  (7)  Insulin Zinc Suspension (Amorphous) Specially Purified Injection—Monocomponent

 

 

  (8)  Insulin Zinc Suspension (Crystalline) Specially Purified Injection—Monocomponent

 

       6.       After Item 131 insert the following item:

“132

Oxycodone Hydrochloride

Treatment in malignant neoplasia”.

       7.       Omit Item 134.

       8.       Omit Item 156, substitute the following item:

“156

‘PREGESTIMIL’

With the written authority of the Permanent Head—

   Cystic fibrosis
Enterokinase deficiency
Patients who are intolerant of both milk protein and soya protein”.

       9.       Omit Item 159, substitute the following item:

“159

Propranolol Tablets, B.P. 160 mg

Hypertension where there is an inadequate response to a daily dose of at least 160 mg of propranolol

Frequent disabling angina without evidence of cardiac failure where there is an inadequate response to a daily dose of at least 160 mg of propranolol”.

     10.       After Item 190A insert the following item:

“190B

Vidarabine

Eye infections caused by Herpes Simplex Virus or by Vaccinia Virus where idoxuridine has proved ineffective”.

 

NOTES

1.       Notified in the Commonwealth of Australia Gazette on 29 July 1980.

2.       Statutory Rules 1960 No. 17 as amended to date. For previous amendments see Note 2 to Statutory Rules 1980 No. 69 and see also Statutory Rules 1980 No. 69.